IP Library Granted Patent US 10,537,568
Granted Patent B2
US 10,537,568 · App. 14/974,930 · Granted Jan 21, 2020

Use of levocetirizine and montelukast to ameliorate inflammation following radiation exposure

Inventor: Bruce Chandler May (Santa Barbara, CA)
Assignee: IRR, Inc.
A61K31/495A61K31/47A61K31/56A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,537,568
App. No.
14/974,930
Granted
Jan 21, 2020
Kind
B2
Abstract

The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient. The combination can be useful during and following radiation exposure to ameliorate the inflammatory response.

Claims (8)

1. A method of treating a patient who has been exposed to radiation comprising administering to the patient an effective amount of a combination of levocetirizine and montelukast wherein the radiation exposure is associated with radiation therapy and wherein the combination ameliorates an inflammatory response associated with the radiation.

2. The method of claim 1 , wherein the combination is administered at a time during radiation exposure.

3. The method of claim 1 , wherein the combination is administered at a time after radiation exposure.

4. The method of claim 1 , wherein the combination is administered in a sequential manner.

5. The method of claim 1 , wherein the combination is administered in a substantially simultaneous manner.

6. The method of claim 1 , further comprising the administration of a steroid.

7. The method of claim 1 , wherein the combination is administered to the patient by one or more of the routes consisting of enteral, intravenous, intraperitoneal, inhalation, intramuscular, subcutaneous and oral.

8. The method of claim 7 , wherein the levocetirizine and montelukast are administered by the same route.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2018
From: MAY, BRUCE CHANDLER
To: IRR, INC.
Reel/Frame 047724/0470 →
Continuity (4)
Continuation 14704444 · May 5, 2015
Continuation 13704589
Provisional Application 61355520 · Jun 16, 2010
Related Publication 20160175301A1 · Jun 23, 2016